Topical Patents (Class 514/928)
  • Patent number: 8946295
    Abstract: A method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell re-growth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 3, 2015
    Assignee: Sunny Pharmtech Inc.
    Inventor: Yih-Lin Chung
  • Patent number: 8912165
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: December 16, 2014
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Patent number: 8802133
    Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 12, 2014
    Assignee: Advanced Bio-Technologies, Inc.
    Inventor: Paul Guilbaud
  • Patent number: 8632823
    Abstract: Super-oxidized water based on hypochlorous acid, such as is obtained by the electrochemical treatment of a saline solution, may be used in the treatment of leg ulcers or other open wounds. Preferably, the pH of the super-oxidized water is in a range of 4 to 7, and the water has a redox potential of >950 mV. Medicaments based on the super-oxidized water may be in liquid or gel form. The super-oxidized water is able to control the microbial population within the wound and at the same time permit cell proliferation.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: January 21, 2014
    Assignee: Puricore, Inc.
    Inventor: Joe B. Selkon
  • Patent number: 8536231
    Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: September 17, 2013
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 8486375
    Abstract: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: July 16, 2013
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini
  • Patent number: 8415159
    Abstract: The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 9, 2013
    Assignee: Mesynthes Ltd.
    Inventors: Brian Roderick Ward, Keryn Dallas Johnson, Barnaby Charles Hough May
  • Patent number: 8207233
    Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: June 26, 2012
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 8207234
    Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: June 26, 2012
    Assignee: University of Southern California
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 8187614
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: May 29, 2012
    Assignee: Legere Pharmaceuticals, Ltd.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 8119106
    Abstract: The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: February 21, 2012
    Assignee: Foamix Ltd
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini
  • Patent number: 7824713
    Abstract: A method for treating diaper rash, leg ulcers and bed sores using super hydrated bacteriostatic topical preparation with a stable acid pH 5.82, by applying this topical application, which is a mixture of anhydrous lanolin (USP), water, boric acid powder (USP), edible corn starch, white petrolatum, cosmetic grade, and zinc oxide ointment (USP 20% zinc oxide) mixed in a paddle mixer at a temperature of about 100° F. to 107° F. then applying topically, the super hydrated bacteriostatic preparation, at room temperature, on the rash, leg ulcers, or bed sores.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: November 2, 2010
    Inventor: Wallace W. Shong
  • Patent number: 7790672
    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: September 7, 2010
    Assignee: Legere Pharmaceuticals, Inc.
    Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
  • Patent number: 7648968
    Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of dermal ulcers. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: January 19, 2010
    Assignee: Novogen Research Pty. Ltd.
    Inventor: Graham Edmund Kelly
  • Patent number: 7622506
    Abstract: This invention relates to compositions containing a compound of formula (I) shown below: Each variable is defined in the specification. Also disclosed are methods of using these compositions to treat acne, psoriasis, and infective skin ulcer.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 24, 2009
    Assignee: SunTen Phytotech Co., Ltd.
    Inventors: Du-Shieng Chien, Yi-Wen Chu, Wu-Chang Chuang, Ming-Chung Lee
  • Patent number: 7517528
    Abstract: Epidermal growth factor (EGF) produced by an excretory recombinant approach was tested for its efficacy in treating various skin wounds. In a randomized double blind controlled study, local cream samples prepared with human EGF at a final concentration of as low as 0.02% (g/g) in topically suitable carrier were found to have an enhancing effect on the recovery of diabetes foot ulcers. This promotional effect is statistically significant and has resulted in a reduced mean healing time of over 3 weeks when compared with that of control. Both the 0.02% (g/g) and 0.04% (g/g) human EGF supplemented samples in comparison with control showed a trend of stimulatory effect when a recovery of 50% of an ulcer was considered. The EGF samples were also shown to be highly effective in promoting treatments of wounds resulting from bedsores and surgeries.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: April 14, 2009
    Assignee: Bio-Click Technologies, Ltd.
    Inventors: Wan Keung Raymond Wong, Kat-Hon Lam, Man-Wo Tsang
  • Patent number: 7250397
    Abstract: Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions particularly as medicaments.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: July 31, 2007
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, David Knott
  • Patent number: 7109237
    Abstract: A water-in-oil emulsion containing ascorbic acid and, as an emulsifier, a dimethiconecopolyol or an alkyldimethiconecopolyol, where the aqueous phase having a pH ranging from 5.5 to 7.5. This emulsion allows ascorbic acid to be stabilized and can be used, in particular, in the cosmetics and/or dermatological fields. The invention also relates to a cosmetic process for treating the skin using the emulsion.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: September 19, 2006
    Assignee: L'Oreal
    Inventors: Isabelle Afriat, Florence Chanvin
  • Patent number: 6958159
    Abstract: The present invention relates to an improved pharmaceutical composition useful for the topical treatment of burns, cuts, wounds, abrasions and the like, and to methods of treatment of injured body surfaces such as skin.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: October 25, 2005
    Assignee: Chiltern Pharmaceuticals, Pty Ltd.
    Inventor: Robert Alan Smith
  • Patent number: 6932966
    Abstract: A skin treatment mixture for treating pierced skin such as that resulting from a body piercing procedure includes sea salt, lysozyme and reconstituted ocean water. The reconstituted ocean water preferably is the product of reverse osmosis of water. The skin treatment mixture preferably additionally includes sodium benzoate to act as a preservative. A method of producing a skin treatment mixture includes the steps of providing a quantity of purified water; adding a quantity of sea salt to the quantity of purified water; boiling the purified water and sea salt; cooling the purified water and sea salt; adding a quantity of lysozyme to the purified water and sea salt; sterilizing the mixture and testing it for bacteria. A method of treating a pierced skin area includes the step of applying to the pierced area a reconstituted ocean water mixture of sea salt and lysozyme.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: August 23, 2005
    Inventor: Edward Kolos
  • Patent number: 6828313
    Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: December 7, 2004
    Assignee: Savient Pharmaceuticals, Inc.
    Inventor: Don Fishbein
  • Patent number: 6767559
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: July 15, 2002
    Date of Patent: July 27, 2004
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6759436
    Abstract: A clear aqueous formulation for topical application in the oral cavity of humans to treat leukoplakia contains water, &bgr;-carotene, a water miscible polyol, an unsaturated fatty acid ester, and a surfactant, preferably polyethoxylated castor oil. The formulation preferably also contains a pharmaceutically acceptable anti-oxidant, preferably d-alpha-tocopherol (vitamin E), and is in the form of an oral rinse or as a gel well suited for spreading on gums or other parts of the oral cavity. The formulation is applied in a gel form on a substantially regular daily basis to areas in the oral cavity where leukoplakia lesions are present. Persistent application of the gel results in substantial diminution or total elimination of the leukoplakia lesions.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: July 6, 2004
    Assignee: Micelle Products, Inc.
    Inventors: Wenjie Li, Edward Alosio, David A. Rutolo, Jr., Bricini Faith (Bim) Dema-Ala
  • Patent number: 6696433
    Abstract: The present application relates to the use of compounds that influence the sex hormone system for the treatment of wounds and/or fibrotic disorders. Preferred compounds for use in such treatments are steroid hormones and especially the oestrogens.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: February 24, 2004
    Assignee: Renovo Limited
    Inventors: Mark W J Ferguson, Gillian S Ashcroft
  • Patent number: 6669966
    Abstract: Skin-growth-enhancing compounds and compositions including a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and Ag(I,III) oxide, or a combination thereof. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. Also included are articles containing such compositions, such as wound dressings, and methods for facilitating or enhancing skin growth using these compounds, compositions, and articles, such as for the treatment or management of burns or skin grafts.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: December 30, 2003
    Assignee: Marantech Holding LLC
    Inventor: Marvin S. Antelman
  • Patent number: 6565895
    Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: May 20, 2003
    Assignee: GelTex Pharmaceuticals, Inc.
    Inventors: Philip J. Goddard, Jeffrey D. Klinger, Pradeep K. Dhal, W. Harry Mandeville, III, Richard J. Fitzpatrick, Thomas X. Neenan
  • Patent number: 6555125
    Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions. The compositions of the present invention may also be combined with materials capable of forming seals over ulcers or lesions to further promote the healing process.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: April 29, 2003
    Inventor: Phillip Campbell
  • Patent number: 6506393
    Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: January 14, 2003
    Assignees: Zentaris AG, Max-Planck Gesellschaft zur Forderung der Wissenchaften e.V.
    Inventors: Hansjörg Eibl, Clemens Unger, Jürgen Engel
  • Patent number: 6492434
    Abstract: A cyanoacrylate adhesive is applied onto intact surface skin areas prone to ulceration so as to inhibit formation of surface skin ulcers.
    Type: Grant
    Filed: February 27, 1995
    Date of Patent: December 10, 2002
    Assignee: Flowers PArk Ltd.
    Inventors: Leonard V. Barley, Jr., Michael M. Byram, Patrick J. Tighe, Richard J. Greff
  • Patent number: 6489317
    Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: December 3, 2002
    Inventor: Thomas Julius Borody
  • Patent number: 6455565
    Abstract: A pharmaceutical composition of water, water soluble vinyl polymer gel, amine alcohol dispersant and IEP is used topically to treat herpes labialis and aphthous stomatitis lesions, and also to treat herpes genitalis, chicken pox, allergic conjunctivitis, giant papillary conjunctivitis, stomatitis secondary to chemotherapy, thermal burn, sunburn, and decubitus ulcers and shingles.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: September 24, 2002
    Assignee: Professional Pharmaceutical, Inc.
    Inventors: Bruce A. Jack, B. Thomas White
  • Patent number: 6444232
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: September 3, 2002
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6432426
    Abstract: Non-staining topical iodine disinfecting compositions having the ability to inactivate pathogens associated with skin infections or diseases. based upon the presence of molecular iodine in a concentration above at least 15 ppm. Any other iodine species selected from the group consisting of complexed iodine and triiodide may be present with the total of such other iodine species limited to a concentration of less than about 700 ppm so that any visible stain resulting from the application of this composition on the skin will dissipate without leaving any visible skin coloration.
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: August 13, 2002
    Assignee: Symbollon Corporation
    Inventor: Jack Kessler
  • Patent number: 6399108
    Abstract: The present invention is directed to methods and compositions for treating skin disorders. The present invention is easily administered and can be used for both humans and animals. The compositions of the present invention comprise borate compounds and provide relief from skin disorder symptoms and lesions. Additionally, the present invention can be used to provide long term maintenance of symptom-free skin.
    Type: Grant
    Filed: June 30, 2000
    Date of Patent: June 4, 2002
    Assignee: P.H.C., Inc.
    Inventor: Don H. Girvan
  • Patent number: 6379651
    Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Josman Laboratories
    Inventor: Narayan Athanikar
  • Publication number: 20020044956
    Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions. The compositions of the present invention may also be combined with materials capable of forming seals over ulcers or lesions to further promote the healing process.
    Type: Application
    Filed: October 17, 2001
    Publication date: April 18, 2002
    Inventor: Phillip Campbell
  • Patent number: 6372717
    Abstract: The invention concerns the use of peptides of general formula R1-L-Tyr-L-Arg-R2 in which R1=H or a R3-C=0 with R3=a C1 to C20 alkyl chain, linear or branched, saturated or unsaturate, hydroxylated or not, or with R3=an aryl, aryl-alkyl or alkyloxy or aryloxy or arylalkyloxy group, and in which R2=OH or a O-R4 group with R4=a C1 to C20 alkyl chain, or R2=a NH2, NHX or NXX group with X=a C1 to C4 alkyl chain. The peptides have a soothing effect on the skin, including by topical application, and attenuates the effects of benign skin sores (after shave irritation, sunstroke, frostbite, chaps, depilation). They are used in acceptable cosmetic excipients and in effective in vivo concentrations.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: April 16, 2002
    Assignee: Sederma S.A.
    Inventor: Daniel Greff
  • Patent number: 6352711
    Abstract: Pharmaceutical compositions are provided which comprise effective amounts of antimicrobials, anti-inflammatories, and antihistamines, to provide an ulcer medication which prevents secondary infections and promotes healing while providing immediate relief from pain. The composition may be used to treat a variety of ulcers including but not limited to intraoral aphthous ulcers and non-oral lesions.
    Type: Grant
    Filed: November 30, 1999
    Date of Patent: March 5, 2002
    Inventor: Phillip Campbell
  • Patent number: 6261577
    Abstract: Non-staining topical iodine disinfecting compositions having the ability to inactivate pathogens associated with skin infections or diseases. based upon the presence of molecular iodine in a concentration above at least 15 ppm. Any other iodine species selected from the group consisting of complexed iodine and triiodide may be present with the total of such other iodine species limited to a concentration of less than about 700 ppm so that any visible stain resulting from the application of this composition on the skin will dissipate without leaving any visible skin coloration.
    Type: Grant
    Filed: November 30, 1998
    Date of Patent: July 17, 2001
    Assignee: Symbollon Corporation
    Inventor: Jack Kessler
  • Patent number: 6258385
    Abstract: The invention relates to the use of electron active molecular crystals comprising tetrasilver tetroxide (Ag4O4) for the treatment and cure of dermatological skin conditions (diseases) ranging from dermatitis, acne and psoiasis to herpes and skin ulcers.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: July 10, 2001
    Assignee: Marantech Holding, LLC
    Inventor: Marvin S. Antelman
  • Patent number: 6254879
    Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: July 3, 2001
    Assignees: Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V., Asta Medica AG
    Inventors: Hansjörg Eibl, Clemens Unger, Jürgen Engel
  • Patent number: 6190671
    Abstract: A drug containing, in particular, fractions of the envelopes of bacteria of genera Beggiatoa and Vitreoscilla. The drug is particularly useful for treating ear, nose and throat infections or bronchopulmonary infections.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: February 20, 2001
    Assignee: L'Oreal
    Inventors: Lucien Aubert, Richard Martin
  • Patent number: 6166084
    Abstract: The present invention provides the use of N-acetyl cysteine and its pharmaceutically acceptable salts and derivatives, for the preparation of a composition for treatment or prophylaxis of chronic ulcers. In particular, the treatment of venous ulcers, diabetic ulcers and decubitis ulcers.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: December 26, 2000
    Assignee: Johnson & Johnson Medical, Ltd.
    Inventor: Stephen Bloor
  • Patent number: 6147053
    Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity.
    Type: Grant
    Filed: November 24, 1998
    Date of Patent: November 14, 2000
    Assignee: Merck Patent Gesellschaft MIT
    Inventor: Berthold Nies
  • Patent number: 6110506
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 29, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6063757
    Abstract: A method is provided for healing chronic wounds in a subject, particularly wounds which exhibit poor vascularization and sensory loss. The treatment method involves administering a therapeutically effective amount of .beta.-NGF to the subject to heal the wound. Compositions containing .beta.-NGF for use in the wound healing methods are provided.
    Type: Grant
    Filed: November 27, 1996
    Date of Patent: May 16, 2000
    Inventor: Richard G. Urso
  • Patent number: 6063817
    Abstract: The present invention relates to methods of preventing, or reducing the severity of, an ischemic injury originating in an animal's dermal tissue by applying to the animal a composition comprising a compound of formula I*: ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in whichX is --O--CO--, --NH--CO--, --CS--NH--, --CO--O--, --CO--NH--, --COS--, --SCO--, --SCH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 --NH--, --COCH.sub.2 --, --NHCS--, --CH.sub.2 S--, --CH.sub.2 O--, --OCH.sub.2 --, --NHCH.sub.2 -- or --CR.sup.5 .dbd.CR.sup.6 --;n is 1 or 0;R.sup.m and R.sup.k are independently hydrogen, halogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy or nitro;R.sup.4 is --(CH.sub.2).sub.t --Y.sup.b, C.sub.1-6 alkyl, or C.sub.3-6 cycloalkyl;R.sup.1 is --CO.sub.2 Z, C.sub.1-6 alkyl, CH.sub.2 OH, --CONHR.sup.y, or CHO;R.sup.a and R.sup.b are independently hydrogen or C.sub.1-6 alkyl, or R.sup.a and R.sup.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: May 16, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Shannon, Karyn A. Monte, Kenneth Tramposch
  • Patent number: 6048552
    Abstract: The present invention provides DASC compositions, which upon introduction into aqueous solutions, form stable, non-gritty suspensions. The present invention also provides stable, non-gritty suspensions comprising the DASC compositions of the present invention admixed in aqueous solutions. In addition, the present invention provides processes for preparing the suspensions which comprise admixing the DASC compositions of the present invention with aqueous solutions. Finally, the present invention provides processes for preparing the DASC compositions of the present invention.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: April 11, 2000
    Assignee: Chattem Chemicals, Inc.
    Inventors: Joel Swinson, Richard D. Giles, Jack Pitkin, Glenda Fleming, David B. Blum
  • Patent number: 6046178
    Abstract: A medication and method for treating wounds by contacting the wound, for a sufficient period of time, with a therapeutically effective amount of a starch hydrolysate composition including trace elements, to beneficiate the wound healing processes. A possible starch hydrolysate is maltodextrin and possible trace elements include, at least copper and zinc. The composition may also contain ascorbic acid as well as antibacterial and nutritive agents to promote formation and growth of granulation tissue.
    Type: Grant
    Filed: April 18, 1997
    Date of Patent: April 4, 2000
    Assignee: DeRoyal Industries, Inc.
    Inventor: Anthony N. Silvetti, Sr.
  • Patent number: 6033664
    Abstract: The present invention relates to the use of non-bacterial plasminogen activators in the manufacture of a topical medical preparation for the treatment of slow- or non-healing wounds. In addition, the present invention relates to a composition comprising a physiologically acceptable carrier and an effective amount of a non-bacterial plasminogen activator, with the exclusion of t-PA. Finally, the present invention is directed to a method of treatment of slow- or non-healing wounds comprising the topical application of a non-bacterial plasminogen activator to the site of a wound.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: March 7, 2000
    Assignee: Nederlandse Organisatie voor toegepast-natuurwetenschappelijk onderzoek TNO
    Inventor: Johan Hendrikus Verheijen